Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by WalkOverTheStrton Aug 22, 2021 5:09pm
362 Views
Post# 33746539

RE:RE:RE:RE:RE:RE:Buyout

RE:RE:RE:RE:RE:RE:BuyoutListen to the CEO explain their evolution of the software/tech in the link below.

He admits earlier on it was clunky / difficult to use (the earier version) which is why it wasn't easy to sell.  So they improved upon it so now it is near painless for the user / even made the UX the same as GEHC software feel and touch.
They also are adding further improvements 4D and the ability to see the twisting of the heart to show further capabilities to GE and other potential customers.

And realize that for the last 18 months they have not been able for the most part to interact in person on demos or sales calls... Not an easy environment and this video also calls out the even slower beauracry of the heathcare / hospital system.

It is now in the stage the tech works well and is ready for prime time. That is where GEHC comes in to roll it out to their sales staff (training in progress and understand to be completing soon) and why they have mentioned dirstributors for Europe. 

The question now is how long once final acceptance testing is done and GE sales staff is trained will the sales cycle take? 


https://www.youtube.com/watch?v=c6ETk2SkPss
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse